Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis

• Asıl Yazarlar: Tereza Gabelić (Yazar), Barbara Barun (Yazar), Ivan Adamec (Yazar), Magdalena Krbot Skorić (Yazar), Mario Habek (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Taylor & Francis Group, 2021-11-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Traditionally, the management of active relapsing remitting MS was based on the, so-called, maintenance therapy, which is characterized by continuous treatment with particular disease modifying therapy (DMT), and a return of disease activity when the drug is discontinued. Another approach is charact...